Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Publication Type:
Journal ArticleSource:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015)Abstract:
Aurora A kinase (AAK) is upregulated in highly proliferative lymphomas, suggesting its potential as a therapeutic target. Alisertib is a novel oral AAK inhibitor without adverse safety signals in early-phase studies that demonstrated preliminary activity in T-cell lymphoma. This phase II study was conducted to further investigate the efficacy of alisertib in relapsed or refractory peripheral T-cell non-Hodgkin lymphoma (PTCL).
Doing Business with Arnold Library
Weintraub Building, B1-010
(206) 667-4314
library@fredhutch.org
More About Arnold Library
Quick Links
- ILLiad/ILL Form
- Journals List
- Ovid - Medline
- Web of Science
- Pubmed
- Libguides
- Library Catalog
- Researcher Profiles
- Library Affiliations & Memberships
- Fred Hutch Papers (Intranet)